23andMe, born from the techno-optimism of the Human Genome Project, revolutionized direct-to-consumer genetic testing. But with its valuation now in freefall, mounting layoffs and its board resigning ...

Interest in genetic data is on the rise, driven by the growth of direct-to-consumer (DTC) genetic testing and its value for AI in drug development and personalized medicine. Historically, gaps in ...

Decades after researches first sequenced the human genome, scientists throughout the world are still working to understand it. Despite diligent global efforts to link uncommon variations in DNA ...

The recent $30 million settlement between 23andMe and 6.4 million users following a major data breach offers important lessons for businesses dealing with sensitive genetic and genomic information.

As genetic testing and genome sequencing become part of everyday healthcare, questions about privacy, consent, and data security are more urgent than ever. Sensitive DNA information can reveal not ...

In the last few years consumer genomics has grown in both its offerings and legitimacy. The industry that was once best known for telling clients if they were Italian or Hungarian is now securing its ...

Genomic data is rapidly reshaping drug development, but not all data delivers the same value. For biopharma teams, the ability to accurately identify patients, understand disease burden, and make ...

DIGITizE convened key stakeholders from health information technology and management vendors, academic health centers, government agencies, and other organizations to work together to examine how ...